This study aims to review the outcomes of ongoing clinical studies on stem cells in Severe Acute Respiratory Syndrome (SARS), Acute Respiratory Distress Syndrome (ARDS), and Middle East Respiratory Syndrome (MERS). The results will be associated with possible applications to COVID-19.
The above paper was done in Australia showing how iPSC MSC can be use to repair lung tissues and airwasy in 2017.
The above paper was done in the USA using umbilical cord stem cells to show clinically the benefits of stem cells for Aging Fraility in 2017.
The above paper show how umbilcial cord stem cells greatly improve Osteoarthritis and reduces pain in a clinical study in 2018.
“The generation of glucose-responsive islet-like organoids that are able to avoid immune detection provides a promising alternative to cadaveric and device-dependent therapies in the treatment of diabetes.” Evans further suggested, “We now have a product that could potentially be used in patients without requiring any kind of device.”
“The current and future clinical applications of cell lines are bountiful,” Dr Feldman concluded, a sentiment echoed by Dr Reubinoff, who stated, “It is becoming increasingly essential to consider GMP compliance, safety, and regulatory criteria as stem cell lines become poised for clinical applications.”
At Regenerative Medicine Limited, we pride ourselves on the ability to change and impact lives in a healthy way. Curious to find out more? Get in touch with a member of our team today.
